CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be
a) a guide for reporting for authors of RCTs,
b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.
Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.
In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).
Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):
Eysenbach G, CONSORT-EHEALTH Group
CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions
J Med Internet Res 2011;13(4):e126
URL: http://www.jmir.org/2011/4/e126/
URL: http://www.jmir.org/2011/4/e126/
doi: 10.2196/jmir.1923
PMID: 22209829

* Required

Your name *
First Last

Jing Wang

Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada
University of Texas Health Science Cen

Your e-mail address *
abc@gmail.com
jing.wang@uth.tmc.edu

Title of your manuscript *
Provide the (draft) title of your manuscript.

A Behavioral Lifestyle Intervention Enhanced with Multiple-Behavior Self-Monitoring Using Mobile and Connected Tools: A Pilot Comparative Effectiveness Trial among Underserved Individuals with Type 2 Diabetes and Comorbid Overweight or Obesity

Name of your App/Software/Intervention *
If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

Loselt!
Evaluated Version (if any)
e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Your answer

Language(s) *
What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App *
e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

https://play.google.com/store/apps/dl

URL of an image/screenshot (optional)

Your answer

Accessibility *
Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
access is open to everyone, but requires payment/subscription/in-app purchases

app/intervention no longer accessible

Other:

Primary Medical Indication/Disease/Condition *
e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Diabetes with co-morbid overweight or

Primary Outcomes measured in trial *
comma-separated list of primary outcomes reported in the trial

Feasibility

Secondary/other outcomes
Are there any other outcomes the intervention is expected to affect?

Your answer

Recommended "Dose" *
What do the instructions for users say on how often the app should be used?

Approximately Daily

Approximately Weekly
Approximately Monthly
Approximately Yearly
"as needed"
Other:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months *

unknown / not evaluated
0-10%
11-20%
21-30%
31-40%
41-50%
51-60%
61-70%
71%-80%
81-90%
91-100%
Other:

Overall, was the app/intervention effective? *

yes: all primary outcomes were significantly better in intervention group vs control
partly: SOME primary outcomes were significantly better in intervention group vs control
○ no statistically significant difference between control and intervention

○ potentially harmful: control was significantly better than intervention in one or more outcomes

○ inconclusive: more research is needed

○ Other:

**Article Preparation Status/Stage** *

At which stage in your article preparation are you currently (at the time you fill in this form)

○ not submitted yet - in early draft status

○ not submitted yet - in late draft status, just before submission

○ submitted to a journal but not reviewed yet

○ submitted to a journal and after receiving initial reviewer comments

○ submitted to a journal and accepted, but not published yet

○ published

○ Other:

**Journal** *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMI R, provide the journal name under "other")

○ not submitted yet / unclear where I will submit this

○ Journal of Medical Internet Research (JMI R)
Is this a full powered effectiveness trial or a pilot/feasibility trial? *

- Pilot/feasibility
- Fully powered

Manuscript tracking number *
If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

- no ms number (yet) / not (yet) submitted to / published in JMIR
- Other: 4478

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title
1a) Does your paper address CONSORT item 1a? *
I.e does the title contain the phrase “Randomized Controlled Trial”? (if not, explain the reason under "other")

☐ yes

☐ Other: It is a pilot comparative effectiveness trial

1a-i) Identify the mode of delivery in the title
Identify the mode of delivery. Preferably use “web-based” and/or “mobile” and/or “electronic game” in the title. Avoid ambiguous terms like “online”, “virtual”, “interactive”. Use “Internet-based” only if intervention includes non-web-based Internet components (e.g. email), use “computer-based” or “electronic” only if offline products are used. Use “virtual” only in the context of “virtual reality” (3-D worlds). Use “online” only in the context of “online support groups”. Complement or substitute product names with broader terms for the class of products (such as “mobile” or “smart phone” instead of “iphone”), especially if the application runs on different platforms.

subitem not at all important

☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ essential

Does your paper address subitem 1a-i? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Multiple-Behavior Self-Monitoring Using Mobile and Connected Tools"

1a-ii) Non-web-based components or important co-interventions in title
Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐
Does your paper address subitem 1a-ii?  
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "A Behavioral Lifestyle Intervention Enhanced with Multiple-Behavior Self-Monitoring Using Mobile and Connected Tools"

1a-iii) Primary condition or target group in the title
Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

Does your paper address subitem 1a-iii?  
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "among Underserved Individuals with Type 2 Diabetes and Comorbid Overweight or Obesity"

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIFvmrTShkZQL2-3Q6O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q1lN...
1b-i) Key features/functionality/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionality/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important 1 2 3 4 5 essential

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "behavior intervention with smart phone based self-monitoring, 2) Behavior intervention with paper diary based self-monitoring, and 3) Usual care group" "The mobile group received an android-based smart phone with two applications loaded to help them record their diet, physical activity, weight, and blood glucose, along with a connected glucometer, while the paper group used paper diaries for these recordings."

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like “fully automated” vs. “therapist/nurse/care provider/physician-assisted” (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)
Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "Both the mobile and paper groups received a total of 11 face-to-face group sessions in a 6-month intervention."

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use “blinded” or “unblinded” to indicated the level of blinding instead of “open”, as “open” in web-based trials usually refers to “open access” (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it).

Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "A total of 26 overweight or obese patients with T2DM were recruited from an underserved minority community health center in Houston, TX. "
from an underserved minority community health center in Houston, TX. "Both the mobile and paper groups received a total of 11 face-to-face group sessions in a 6-month intervention. " The following does not apply- "Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials)"

1b-iv) RESULTS section in abstract must contain use data
Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 1b-iv?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

yes, "A total of 26 patients were enrolled, 11 in the mobile group, 9 in the paper group, and 6 in the control group." "We had 96% retention rate at 6 months." "We did not find statistical significance on % weight loss (P=.20) and HbA1c changes (P=.44) among the 3 groups overtime, however, we found a large effect size of .40 for weight loss and a medium effect size of .28 for glycemic control."

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials
Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)
INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution
Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in “Methods” under 5)
Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "More innovative and practical strategies are needed to address such disparity and improve glycemic control for underserved T2DM patients. ""we propose to fill the scientific gap in testing a behavioral lifestyle intervention for underserved T2DM patients using mHealth tools to enhance multiple-behavior self-monitoring of diet, physical activity, weight, and blood glucose in a pilot comparative effectiveness trial. "

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "Current research comparing the effectiveness of mobile health (mHealth), such as PDA or smartphone applications, versus..."
technology (mHealth), such as PDAs or smartphone applications, versus paper diaries to support self-monitoring did not find significant difference on weight loss outcome in several behavioral weight loss trials [21, 22]. Moreover, these weight loss trials focused on obese populations only [21, 22]; no study compared the two modalities in T2DM patients with co-morbid overweight or obesity. While there are studies testing the use of mHealth tools for diet, physical activity, and blood glucose self-monitoring as part of a health coaching intervention in T2DM patients [23, 24], none of these studies compared the two self-monitoring modalities. Based on self-regulation theory, we hypothesized that monitoring multiple behaviors (i.e., calorie and fat consumption, exercise, and carbohydrate intake) and associated health outcomes (i.e., weight and blood glucose levels) simultaneously can result in behavior change through better self-awareness of how eating and exercise play a role in both weight and glycemic control (Figure 1). 

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Thus, we propose to fill the scientific gap in testing a behavioral lifestyle intervention for underserved T2DM patients using mHealth tools to enhance..."
intervention for underserved T2DM patients using mHealth tools to enhance multiple-behavior self-monitoring of diet, physical activity, weight, and blood glucose in a pilot comparative effectiveness trial. Based on self-regulation theory, we hypothesized that monitoring multiple behaviors (i.e., calorie and fat consumption, exercise, and carbohydrate intake) and associated health outcomes (i.e., weight and blood glucose levels) simultaneously can result in behavior change through better self-awareness of how eating and exercise play a role in both weight and glycemic control (Figure 1). In this study, we sought to assess the feasibility of this mHealth-enhanced intervention and compare its preliminary efficacy with that of paper-based multiple-behavior monitoring and standard diabetes care and education in improving glycemic outcomes among overweight or obese adults with T2DM living in underserved communities."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "We conducted a 3-group pilot randomized controlled clinical trial comparing the efficacy of a behavioral lifestyle intervention modified for underserved populations"

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We conducted a 3-group pilot randomized controlled clinical trial comparing the efficacy of a behavioral lifestyle intervention modified for underserved populations"
this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: eHealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other “unexpected events” that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes “Individuals were included if they 1) had a diagnosis of T2DM for at least 6 months, 2) did not have a diagnosis of end-stage renal disease or cancer, and 3) were physically capable of participating in an internet-based intervention.”
months by self-report and later confirmed in the electronic health records, 2) were overweight or obese (BMI > 25), 3) were 21-75 years old, 4) were able to read and write in English, and 5) had completed or were about to complete the basic diabetes self-management education offered at the recruitment site. Individuals were excluded if they 1) had a history of severe psychiatric disorders (e.g. bipolar disorder, or schizophrenia), 2) were unable to perform regular activity, 3) were currently or planned to be pregnant or nursing in the next 6 months, 4) had a planned vacation in the next 6 months, 5) had previously participated in an intensive behavioral lifestyle intervention, or 6) had substance abuse in the past year." 

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit “de facto” eligibility criterion - this should be explicitly clarified.

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

We provided smartphones to those who did not own one, so this is not one of our eligibility criteria.

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was
possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "Participants were recruited from an American Diabetes Association certified diabetes education program located in a community health center primarily serving uninsured or underinsured individuals living in Harris County, TX. Flyers were distributed to the patients attending diabetes self-management education classes by their diabetes educators. " "All of the outcome measures were administered at baseline, 3 months, and 6 months. Physical measurements and a blood samples were obtained at the study sites. "

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer
4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Participants were recruited from an American Diabetes Association certified diabetes education program located in a community health center primarily serving uninsured or underinsured individuals living in Harris County, TX. Flyers were distributed to the patients attending diabetes self-management education classes by their diabetes educators."

4b-i) Report if outcomes were (self-)assessed through online questionnaires
Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |

Does your paper address subitem 4b-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable to our study, we did not use online questionnaires, since we had face-to-face data collection visits.
had face-to-face data collection visits.

4b-ii) Report how institutional affiliations are displayed
Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

Does your paper address subitem 4b-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners
Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a “Conflict of interest” section or mentioned elsewhere in the manuscript).
5-i) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

5-ii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was “frozen” during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was “frozen” during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).
Does your paper address subitem 5-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

| 1 | 2 | 3 | 4 | 5 | essential |
|---|---|---|---|---|-----------|
| ☐ | ☐ | ☐ | ☐ | ☐ |            |

5-iv) Quality assurance methods
Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

| 1 | 2 | 3 | 4 | 5 | essential |
|---|---|---|---|---|-----------|
| ☐ | ☐ | ☐ | ☐ | ☐ |            |

Does your paper address subitem 5-iv?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used
Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.
Does your paper address subitem 5-v?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

5-vi) Digital preservation
Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

Does your paper address subitem 5-vi?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

5-vii) Access
Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained “access to the platform and Internet” [1]. To ensure access for editors/reviewers/readers, consider to provide a “backdoor” login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).
Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes  "For those who did not have a smartphone, we provided a smartphone for use over 6 months. None of the participants assigned to this group owned a smartphone, so all study participants in the group were given a smartphone with two applications downloaded by study team. The participants used the LoseIt! (FitNow, Inc, Boston, MA) smartphone application for self-monitoring of diet, physical activity, and weight, and the Diabetes Connect application (PHRQL, Inc., Pittsburgh, PA) connected with MyGlucoHealth, a Bluetooth-enabled glucometer (Entra Health Systems LLC, San Diego, CA). "

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who...
Includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

| subitem not at all important | 1 | 2 | 3 | 4 | 5 |
|-----------------------------|---|---|---|---|---|

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "In addition to receiving usual diabetes care and education at the recruiting community center, both the mobile and paper groups received a standard behavioral lifestyle intervention comprising 11 group sessions—weekly for month 1, biweekly for months 2-3, and monthly for months 4-6—and an individual session after month 3. The group sessions were held at the recruiting community health center and included a grocery shopping trip, and pedometers, weight scales, and food scales were distributed in the sessions. The topics for the 11 sessions were: 1) Welcome to the Program, 2) Be a Fat and Calorie Detective, 3) Healthy Eating, 4) Grocery Shopping and Cooking, 5) Move Those Muscles, Jump Start Your Activity Plan, 6) Tip the Calorie Balance, Take Charge of What’s Around You, 7) Problem Solving, Stress, and Time Management, 8) Four Keys to Healthy Eating Out, Make Social Cues Work for You, 9) Slippery Slope of Lifestyle Change, Ways to Stay Motivated, 10) Prepare for Long-Term Self-Management, More Volume/Fewer Calories, and 11) Balance Your Thoughts, Strengthen Your Exercise Program. Each session took approximately 1-2 hours.

Two lifestyle counselors were trained using publicly available materials and a DVD and printed training materials from the GLB program (http://www.diabetesprevention.pitt.edu/grouplifestyleoverview.aspx) and the LookAHEAD intervention (https://www.lookaheadtrial.org). Based on GLB and LookAHEAD intervention principles, a standard behavioral intervention program typically includes group sessions focused on the following behavioral
strategies: 1) goal setting, 2) feedback, 3) portion control, 4) cooking class, 5) field trip, 6) social support, 7) incentives, 8) problem solving, 9) relapse prevention, and 10) self-monitoring. All of these strategies in the original 12 core sessions and 4 transition sessions in the first 6 months of the GLB program were integrated and delivered in the 11 group sessions. An individual intervention was added ad hoc to evaluate individualized goals and behavior change plans, review individual weight loss goals, current weight, and diaries, how to tip the calories, and develop specific diet and physical activity goals to reach weight loss goal.

To adapt the intervention for the underserved population, all intervention materials were modified to be at 9th grade reading level. Intervention sessions were delivered at the recruiting community health center that is close to most of the participants’ homes. The grocery shopping trip was also conducted in the neighborhood where the participants typically shop.

Multiple-Behavior Self-Monitoring Intervention for the Mobile and Paper Groups

Participants received training on how to self-monitor their diet and exercise habits, weight, and blood glucose in the first two sessions. Specifically, both groups were instructed to record their exercise activities (minutes and type of activity) and specify the foods they ate; the amount eaten; the number of calories, fat grams, and carbohydrates; their weight; and their blood glucose using a paper diary or an electronic diary depending on their group randomization.

Mobile Group: For those who did not have a smartphone, we provided a smartphone for use over 6 months. None of the participants assigned to this group owned a smartphone, so all study participants in the group were given a smartphone with two applications downloaded by study team. The participants used the LoseIt! (FitNow, Inc, Boston, MA) smartphone application for self-monitoring of diet, physical activity, and weight, and the Diabetes Connect application (PHRQL, Inc., Pittsburgh, PA) connected with MyGlucoHealth, a Bluetooth-enabled glucometer (Entra Health Systems LLC, San Diego, CA).

5-ix) Describe use parameters
Describe use parameters (e.g., intended “doses” and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency,
Does your paper address subitem 5-ix?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-x) Clarify the level of human involvement
Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as “type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered”. It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

Does your paper address subitem 5-x?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer
5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| subitem not at all important |   |   |   |   | ● |
| essential |   |   |   |   | ● |

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "There were no prompts or reminders embedded in these applications, however, we discussed self-monitoring results and encouraged participants to share experience using them during the 11 face-to-face group sessions."

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.)
Does your paper address subitem 5-xii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Participants received training on how to self-monitor their diet and exercise habits, weight, and blood glucose in the first two sessions. Specifically, both groups were instructed to record their exercise activities (minutes and type of activity) and specify the foods they ate; the amount eaten; the number of calories, fat grams, and carbohydrates; their weight; and their blood glucose using a paper diary or an electronic diary depending on their group randomization. " "In addition to receiving usual diabetes care and education at the recruiting community center, both the mobile and paper groups received a standard behavioral lifestyle intervention comprising 11 group sessions—weekly for month 1, biweekly for months 2-3, and monthly for months 4-6—and an individual session after month 3. "

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Feasibility: Retention, Group Session Attendance, Adherence Study feasibility was assessed including recruitment, patient retention, session attendance, and adherence to intervention."
Study feasibility was evaluated using retention rates at 3 and 6 months, group session attendance rates, and adherence to self-monitoring for both intervention groups. Participants in both intervention groups were asked to assess the acceptability of the 6-month behavioral intervention. Focus groups were conducted at the end of the intervention to learn about participants’ experiences and satisfaction with the intervention.

Preliminary Efficacy
All of the outcome measures were administered at baseline, 3 months, and 6 months. Physical measurements and a blood samples were obtained at the study sites.

Primary Outcome Measure-Glycemic Control
Glycemic control was determined by glycolated hemoglobin (HbA1c) levels. Patients were asked to fast for at least 8 hours before the scheduled data collection visits for venipuncture. A healthy breakfast including fresh fruits and breakfast bars was offered after blood draws. Blood samples were then transferred to a biological laboratory for analysis.

Secondary Outcome Measure-Weight
We used a Tanita scale and body fat analyzer (Tanita Corporation of America, Inc., Illinois, USA) to measure weight and body composition while subjects wore light clothing and stood erect with their bare feet on the scale’s footpads.

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed
If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].
Does your paper address subitem 6a-i?
Copy and paste relevant sections from manuscript text

Your answer

6a-ii) Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoptions metrics are important process outcomes that should be reported in any ehealth trial.

Does your paper address subitem 6a-ii?
Copy and paste relevant sections from manuscript text

Your answer

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).
Does your paper address subitem 6a-iii?
Copy and paste relevant sections from manuscript text

Your answer

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size
Describe whether and how expected attrition was taken into account when calculating the sample size.
Does your paper address subitem 7a-i?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes " After consent and enrollment, we assigned each patient with a study ID
number. The study statistician generated a randomization sheet with the group assignment for each study ID. Study participants were then randomly assigned to one the 3 study groups based on the randomization sheet.

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "After consent and enrollment, we assigned each patient with a study ID number. The study statistician generated a randomization sheet with the group assignment for each study ID. Study participants were then randomly assigned to one the 3 study groups based on the randomization sheet.

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Once enrolled, we assigned each patient with a study ID number. The
study statistician generated a randomization sheet with the group assignment for each study ID. Study participants were then randomly assigned to one of the 3 study groups based on the randomization sheet.

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes ". After consent and enrollment, we assigned each patient with a study ID number. The study statistician generated a randomization sheet with the group assignment for each study ID. Study participants were then randomly assigned to one of the 3 study groups based on the randomization sheet.

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn’t

Specify who was blinded, and who wasn’t. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).
Does your paper address subitem 11a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

11a-ii) Discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”
Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”.

Yes  "The study participants were aware of the differences among the three randomization groups during the consenting process."

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)
Does your paper address CONSORT subitem 11b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "To increase study replicability, key differences among the three randomization groups and the behavioral lifestyle intervention in the landmark LookAHEAD trial (intervention materials are publicly available at https://www.lookaheadtrial.org) are presented in Table 1. "

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Mann-Whitney U tests were conducted for comparison between the mobile and paper groups. For the primary outcome, the percentages of weight change over time were compared by Kruskal Wallis test and the percentages of HbA1c change over time were compared by analysis of variance. Sensitivity analyses were conducted using Last Observation Carried Forward (LOCF) method to impute the missing data for participants who withdrew or were lost to follow-up. "

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).
Does your paper address subitem 12a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Sensitivity analyses were conducted using Last Observation Carried Forward (LOCF) method to impute the missing data for participants who withdrew or were lost to follow-up."

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Sensitivity analyses were conducted using Last Observation Carried Forward (LOCF) method to impute the missing data for participants who withdrew or were lost to follow-up."

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64Rdf1AFvrmrTskZQL2-3q6O9hrL5Sw/viewform?hl=en_US&formkey=dGIKd2Z2Q1l…
X26-i) Comment on ethics committee approval

|       | 1 | 2 | 3 | 4 | 5 |
|-------|---|---|---|---|---|
| subitem not at all important |   |   |   |   |   |
| essential |   |   |   |   |   |

Does your paper address subitem X26-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

|       | 1 | 2 | 3 | 4 | 5 |
|-------|---|---|---|---|---|
| subitem not at all important |   |   |   |   |   |
| essential |   |   |   |   |   |

Does your paper address subitem X26-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

|       | 1 | 2 | 3 | 4 | 5 |
|-------|---|---|---|---|---|
| subitem not at all important |   |   |   |   |   |
| essential |   |   |   |   |   |
Does your paper address subitem X26-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, see table 2 and table 3 and Figure 2 CONSORT diagram.

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
Yes in Figure 2 CONSORT diagram.

13b-i) Attrition diagram
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

Does your paper address subitem 13b-i?
Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "All of the outcome measures were administered at baseline, 3 months, and 6 months"

14a-i) Indicate if critical “secular events” fell into the study period
Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or “changes in computer hardware or Internet delivery resources”
Does your paper address subitem 14a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes “The study was completed in 2015”

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes table 2 and table 3.
15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes Table 2. "A total of 61.5% (16/26) of the sample were female, and 69.2% (18/26) were African Americans"

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple “denominators” and provide definitions

Report multiple “denominators” and provide definitions: Report N’s (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.
Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes  Table 3 and Figure 2 CONSORT diagram

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only “users”, with the appropriate caveats that this is no longer a randomized sample (see 18-i).

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "Intention to treat analyses were performed on the primary and secondary outcomes."

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *
Does your paper address CONSORT subitem 17a?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes Table 3 and "Results from the intention to treat analysis on the primary outcome of HbA1c showed that there were no statistical significant group differences on HbA1c level change over 6 months (P=.44), however, a medium effect size of Cohen’s d=.28 was detected for HbA1c changes. At 6 months, participants in the mobile group had an average weight loss of 1.8%, while the paper group had an average of 4% weight gain and the control group had an average of 1.6% weight gain. There were no statistical significant differences among the 3 group on weight changes over time (P=.20). A medium effect size of Cohen’s d=.40 was found for changes on weight outcomes over time."

17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as “average session length”. These must be accompanied by a technical description how a metric like a “session” is defined (e.g., timeout after idle time) [1] (report under item 6a).

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer
17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Sensitivity analysis using LOCF for imputations did not show any statistically significant differences on the HbA1c and weight outcomes."

18-i) Subgroup analysis of comparing only users
A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).
Does your paper address subitem 18-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical “harm” to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. “Unintended effects” also includes unintended positive effects [2].
subitem not at all important ☐ ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 19-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

19-ii) Include qualitative feedback from participants or observations from staff/researchers
Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

subitem not at all important ☐ ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 19-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant
NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group.

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| subitem not at all important |   |   |   |   |   |

essential

Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "To our knowledge, this pilot study is the first to report the feasibility and..."
acceptability of using mobile and connected tools to enhance an evidence-based behavioral lifestyle intervention for the underserved community. We compared the efficacy of standard diabetes care and education with behavioral lifestyle interventions enhanced with either using smartphone applications and a Bluetooth-connected glucometer for self-monitoring of multiple behaviors or paper diaries on improving glycemic outcomes among overweight or obese adults with T2DM living in underserved communities. The feasibility and acceptability of the study were demonstrated by the high retention rates at 3 and 6 months and high rates of patient engagement in using the mobile applications."

22-ii) Highlight unanswered new questions, suggest future research
Highlight unanswered new questions, suggest future research.

Does your paper address subitem 22-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials
Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.
Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Several limitations to this study should be acknowledged. First, the study sample was recruited from an underserved community in an urban setting, so the study findings may not be generalizable to underserved communities in rural areas. Second, the focus of this study was feasibility and acceptability; thus, the study did not have sufficient power to detect group differences. Third, we provided smartphones and Bluetooth-enabled glucometers to the participants because none of the study participants reported owning a smartphone; the adherence to self-monitoring may be different for those who previously owned a smartphone. Fourth, our measure on adherence to self-monitoring of physical activity depended on patient adherence to the recommended physical activity behaviors. While this approach has been used in several other studies [29, 36], it may underestimate the actual adherence to self-monitoring of physical activity. For example, our adherence to self-monitoring of physical activity was lower than adherence dietary self-monitoring, which could suggest that participants did not exercise at all on that particular day, they did not bother to enter 0 for exercise minutes, and instead, they left it blank. Future research should examine the difference between adherence to self-monitoring and adherence to the actual behavior separately. Fifth, our study only looked at the short term outcomes, maintaining long-term effect may be a different challenge that future studies should consider examining. "

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial
21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| ○ | ○ | ○ | ○ | ○ | essential

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| ○ | ○ | ○ | ○ | ○ | essential

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer
OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes Clinicaltrials.gov NCT02858648;

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *
Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES https://clinicaltrials.gov/ct2/show/NCT02858648

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes “This study was supported by the Dean’s Research Award and PARTNERS...”

https://docs.google.com/forms/d/e/1FAIpQLSfZBSU1bwOc_OimqcS64RdflAFvmrTShZQL2-3G809hrL5Sw/viewform?hl=en_US&formkey=dG1Kd2Z2Q1I...
Awards at the Cizik School of Nursing at UTHealth and the Robert Wood Johnson Foundation Nurse Faculty Scholars Program. "Cai’s efforts were supported by the National Institutes of Health’s Clinical and Translational Science Award grant (UL1 TR000371), awarded to the University of Texas Health Science Center at Houston in 2012 by the National Center for Clinical and Translational Sciences."

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

1  2  3  4  5

subitem not at all important

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Your answer

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

○ yes, major changes

○ yes, minor changes
What were the most important changes you made as a result of using this checklist?

Add details on randomization and clarify face-to-face versus mobile app interactions.

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *

4 hours

As a result of using this checklist, do you think your manuscript has improved? *

○ yes
○ no
○ Other:

Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

○ yes
no

Other:

Any other comments or questions on CONSORT EHEALTH

Your answer

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMI R, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!

Click submit so we have your answers in our database!

SUBMIT

Never submit passwords through Google Forms.

This form was created outside of your domain. Report Abuse - Terms of Service - Additional Terms
